| Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from … A Bazarbachi, G Bug, F Baron, E Brissot, F Ciceri, I Abou Dalle, H Döhner, ... haematologica 105 (6), 1507, 2020 | 114 | 2020 |
| Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies I Abu-Dalle, T Reljic, T Nishihori, A Antar, A Bazarbachi, B Djulbegovic, ... Biology of Blood and Marrow Transplantation 20 (11), 1677-1686, 2014 | 114 | 2014 |
| Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia I Abou Dalle, E Jabbour, NJ Short, F Ravandi Current treatment options in oncology 20, 1-13, 2019 | 67 | 2019 |
| The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia I Abou Dalle, CD DiNardo Therapeutic advances in hematology 9 (7), 163-173, 2018 | 64 | 2018 |
| Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in … A Bazarbachi, C Schmid, M Labopin, D Beelen, I Wolfgang Blau, V Potter, ... Clinical Cancer Research 26 (24), 6475-6482, 2020 | 45 | 2020 |
| Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia K Sasaki, HM Kantarjian, T Kadia, K Patel, S Loghavi, G Garcia‐Manero, ... Cancer 125 (21), 3755-3766, 2019 | 42 | 2019 |
| Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib F Yalniz, I Abou Dalle, H Kantarjian, G Borthakur, T Kadia, K Patel, ... American journal of hematology 94 (9), 984-991, 2019 | 41 | 2019 |
| Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation I Abou Dalle, H Kantarjian, SA Bannon, R Kanagal-Shamanna, ... American journal of hematology 95 (2), 227-229, 2020 | 37 | 2020 |
| Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors I Abou Dalle, HM Kantarjian, NJ Short, M Konopleva, N Jain, ... American journal of hematology 94 (12), 1388-1395, 2019 | 32 | 2019 |
| Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment F Kreidieh, I Abou Dalle, N Moukalled, J El-Cheikh, E Brissot, M Mohty, ... International Journal of Hematology 116 (3), 330-340, 2022 | 31 | 2022 |
| Evaluation and management of measurable residual disease in acute lymphoblastic leukemia I Abou Dalle, E Jabbour, NJ Short Therapeutic advances in hematology 11, 2040620720910023, 2020 | 31 | 2020 |
| Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3-mutant acute … I Abou Dalle, A Ghorab, K Patel, X Wang, H Hwang, J Cortes, GC Issa, ... Blood cancer journal 10 (5), 48, 2020 | 30 | 2020 |
| Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States I Abou Dalle, H Kantarjian, J Burger, Z Estrov, M Ohanian, S Verstovsek, ... Cancer medicine 8 (15), 6559-6565, 2019 | 25 | 2019 |
| Primary small cell carcinoma of the breast: a case report I Abou Dalle, J Abbas, F Boulos, Z Salem, HI Assi Journal of Medical Case Reports 11, 1-5, 2017 | 24 | 2017 |
| A phase Ib/II study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed … I Aboudalle, MY Konopleva, TM Kadia, K Naqvi, K Vaughan, M Kurt, ... Blood 134, 176, 2019 | 22 | 2019 |
| 20-year steady increase in survival of adult patients with relapsed philadelphia-positive acute lymphoblastic leukemia post allogeneic hematopoietic cell transplantation A Bazarbachi, M Labopin, M Aljurf, R Niittyvuopio, M Balsat, D Blaise, ... Clinical Cancer Research 28 (5), 1004-1012, 2022 | 19 | 2022 |
| A pilot phase II study of erlotinib for the treatment of patients with relapsed/refractory acute myeloid leukemia I Abou Dalle, JE Cortes, P Pinnamaneni, B Lamothe, A Diaz Duque, ... Acta haematologica 140 (1), 30-39, 2018 | 17 | 2018 |
| Phase I-II study of crenolanib combined with standard salvage chemotherapy and crenolanib combined with 5-azacitidine in acute myeloid leukemia patients with FLT3 activating … I Aboudalle, HM Kantarjian, MN Ohanian, Y Alvarado, EJ Jabbour, ... Blood 132, 2715, 2018 | 15 | 2018 |
| Phase II study of single-agent nivolumab in patients with myelofibrosis I Abou Dalle, H Kantarjian, N Daver, L Masarova, N Pemmaraju, P Bose, ... Annals of Hematology 100, 2957-2960, 2021 | 14 | 2021 |
| Pharmacologic therapies to prevent relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation AI Antar, ZK Otrock, I Abou Dalle, J El-Cheikh, A Bazarbachi Frontiers in Oncology 10, 596134, 2020 | 14 | 2020 |
